VEGFA and age-related macular degeneration: There are significant therapeutic advances for treating the neovascular subtype of AMD, such as intravitreally administered anti-vascular endothelial growth factor substances [10]; however, there are currently no effective, targeted and efficient treatment options for retinal cell degeneration in the atrophic subtype of AMD and in RP [11].